Methylation-dependent silencing of CACNA2D3 was proposed as a biomarker for the risk of development of metastatic disease in breast cancer, where methylation correlated strongly with visceral and metastatic disease independent of α-estrogen receptor expression [108]. The gene discussed is CACNA2D3; the disease is metastatic neoplasm.